Home >> About >> Publications

Dr. Magid Abou Gharbia

Publications: 119

Book Chapters: 5

Invited Lectures & Presentations: 223

Patents and patent applications: US 107, Global: >350

 

Selected peer reviewed journal articles:

  1. Novel compounds that reverse the diseased phenotype in Type 2 Gaucher's disease patient-derived cells, M. Jacobson, W.Childers, R. Fan, R. Martinez, D. Colussi, E. Melenski, Y. Liu, J. ordon and M. Abou-Gharbia, Biorg & MedChem Lett, 30, 126806, 2020.
  2. Design and synthesis of functionalized piperazin-1yl-(E)-stilbenes as inhibitors of 17α-hydroxylase-C17,20-lyase (Cyp17), Benjamin Blass, Pravin Iyer, Magid Abou-Gharbia, Wayne Childers, John Gordon, Mercy Ramanjulu, George Morton, Premkumar Arumugam, Joshodeep Boruwa, John Ellingboe, Sayan Mitra, Rajashekar Reddy Nimmareddy, Shalini Paliwal , Jamallamudi Rajasekhar, Savithiri Shivakumar, Pratima Srivastava, Raghuram S. Tangirala, Konda Venkataramanaiah, and Mahesh Yanamandra, Bioorg Med Chem Lett, 28(13), 2270-2274, 2018.
  3. Targeting CDK9 reactivates epigenetically silenced genes in cancer Hanghang Zhang, Somnath Pandey, Meghan Travers, Jittasak Khowsathit, George Morton, Hongxing Sun, Carlos Barrero, Carmen Merali, Yasuyuki Okamoto, Takahiro Sato, Judit Garriga, Natarajan Bhanu, Bela Patel, Jozef Madzo, Noël J.-M. Raynal, Benjamin Garcia, Marlene A. Jacobson, Salim Merali, Yi Zhang, Wayne Childers, Magid Abou-Gharbia, John Karanicolas, Stephen B. Baylin, Cynthia Zahnow, Jaroslav Jelinek, Xavier Graña and Jean-Pierre J. Issa, Cell, 175, 1244-1258, 2018.
  4. Novel inhibitors of Staphylococcus aureus RnpA that synergize with mupirocin, Nicole Lounsbury; Tess Eidem.; Jennifer Colquhoun; George Mateo; Magid A Abou-Gharbia; Paul M Dunman,; Wayne Childers, Bioorg.Med Chem Lett., 28(6), 1127-1131, 2018.
  5. A mitochondrial-targeted purine-based HSP90 antagonist for leukemia therapy, Kelly G. Bryant, Young Chan Chae, Rogelio L. Martinez, John C. Gordon, Khaled M. Elokeley, Andrew V. Kossenkov, Steven Grant, Wayne E. Childers, Magid Abou-Gharbia and Dario C. Altieri, Oncotarget, 8: 112184-112198, 2017.
  6. Glutamate Transporters-1 (GLT-1): A Potential Therapeutic Target for the Treatment of Central Nervous Diseaes and Disorders, M. Abou-Gharbia, B. Blass, W. Childers, M. Ramanjulu and E. Melenski, Drugs of the Future, 42(8), 489-509, 2017
  7. Nuclear magnetic resonance structure of the human polyoma JC virus agnoprotein, A. Sami Saribas, Pascale Coric, Anahit Hamazaspyan, William Davis, Rachel Axman, Martyn K. White, Magid Abou-Gharbia, Wayne Childers, Jon H. Condra, Serge Bouaziz, and Mahmut Safak, J. Cell Physiol, 118(10), 2115-2127, 2017.
  8. Design, synthesis and SAR of new substitutes pyridopyrimidines as ATP-competive PI3K/mTOR inhibitors, Aisha A. K. Al-Ashmawy, Fatma A. Ragab, Kahled M. Elokely, Manal M. Anwar, Oscar Perez-Leal, Mario C. Rico, John Gordon, Eugeney Bichenkov, George Mateo, Emad M. M. Kassem, Gehan H. Hegazy, Magid Abou-Gharbia and Wayne Childers, Bioorg Med Chem Lett, 27(23), 3117–3122, 2017.
  9. Design, synthesis and evaluation of (2S,4R)-ketoconazole sulfonamide analogs as potential treatment for metabolic syndrome, Benjamin E Blass, Pravin Iyer, Magid Abou-Gharbia, Wayne W Childers, John C Gordon, Mercy Ramanjulu, George Morton, Premkumar Arumugam, Joshodeep Boruwa, John Ellingboe, Sayan Mitra, Rajashekar Reddy Nimmareddy, Shalini Paliwal, Jamallamudi Rajasekhar, Savithiri Shivakumar, Pratima Srivastava, Raghuram S. Tangirala, Konda Venkataramanaiah, and Mahesh Yanamandra, Bioorg Med Chem Lett., 26(23), 5825–5829, 2016.
  10. Resistance to BET bromodomain inhibitors is mediated by kinome reprogramming in ovarian cancer, Alison M. Kurimchak, Claude Shelton, Kelly E. Duncan, Katherine J. Johnson, Jennifer Brown, Shane O’Brien, Rashid Gabbasov, Lauren S. Fink, Yuesheng Li, Nicole Lounsbury, Magid Abou-Gharbia, Wayne E. Childers, Denise C. Connolly, Jonathan Chernoff, Jeffrey R. Peterson, and James S. Duncan, Cell Reports, 16, 1273–1286, 2016 .
  11. 12/15-lipoxygenase inhibition reverses cognitive impairment, brain amyloidosis, and tau pathology by stimulating autophagy in aged triple-transgenic mice, Antonio Di Meco, Jian-Guo Li; Benjamin E. Blass.; Magid Abou-Gharbia, Elizabeth Lauretti and Domenico Pratico,  Biological Psychiatry, 81, 2, 92-100, 2016.
  12. Emerging from the unknown: structural and functional features of agnoprotein of polyomaviruses, A. S. Saribas, P. Coric, A. Hamazaspyan, W. Davis, R. Axman, M. K. White, M. Abou-Gharbia, W. Childers, J. H. Contra, S. Bouaziz and M. Safak, J. Cell Physiol, 231, 2115-2127, 2016.
  13. Design, synthesis, and evaluation of (2S,4R)-Ketoconazole sulfonamide analogs as potential treatments for Metabolic Syndrome, Blass, B. E.; Iyer, P.; Abou-Gharbia, M.; Childers, W. E.; Gordon, J. C.; Ramanjulu, M.; Morton, G.; Arumugam, P.; Boruwa, J.; Ellingboe, J.; Mitra, S.; Nimmareddy, R. R.; Paliwal, S.; Rajasekhar, J.; Shivakumar, S.; Srivastava, P.; Tangirala, R. S.; Venkataramanaiah, K.; Yanamandra, M. Bioorganic & Medicinal Chemistry Letters, 26, 23, 5825-5829, 2016.
  14. Targeting calcium signaling to induce epigenetic reactivation of tumor suppressor genes in cancer, Noël J.-M. Raynal, Justin Lee, Youjun Wang, Judith Garriga, Gabriel Malouf, Sarah Dumont, Elisha J Dettman, Vazganush Gharibyan, Saira Ahmed, Woonbok Chung, Wayne E. Childers, Magid Abou-Gharbia, Ryan A. Henry, Andrew J. Andrews5, Jaroslav Jelinek, Stephen B. Baylin6, Don Gill2, and Jean-Pierre J. Issa, Cancer Research, 76, 1494-1505, 2015.
  15. Novel inhibitors of Staphylococcus aureus RnpA that synergize with mupirocin”, N. Lounsbury, T. Eidem, G. Mateo, M. Abou-Gharbia, P. M. Dunman and W. E. Childers, Bioorg Med Chem Lett, 59, 2016-2028, 2015.
  16. Heterocyclic chalcone activators of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) with improved in vivo efficacy”, N. Lounsbury, G. Mateo, B. Jones, S. Papaiahgari, R. K. Thimmulappa, C. Teijaro, J. Gordon, K. Korzekwa, M. Ye, G, Allaway, M. Abou-Gharbia, S. Biswal and W. E. Childers, Jr.,   Bioorg Med Chem, 23(17): 3552-3559, 2015.
  17. Pharmacologic blockade of 12/15-lipoxygenase ameliorates memory deficits, Aβ and tau neuropathology in the triple-transgenic mice, Chu, J.; Li, J.-G.; Giannopoulos, P. F.; Blass, B. E.; Childers, W.; Abou-Gharbia, M.; Pratico, D. Molecular Psychiatry, 20,11, 1329-133, 2015
  18. Small-Molecule inhibitors of Staphylococcus aureus RnpA-Mediated RNA Turnover and rRNA Processing, Tess E. Eidem, Nicole Lounsbury, John F. Emery, Jeffrey Bulger, Andrew Smith, Magid Abou-Gharbia, Wayne Childers and Paul M. Dunman , Antimicrob Agents Chemother, 59(4),  2015, 2016-2028.
  19. Discovery of first-in- class therapeutics-venlafaxine(Effexor), desvenlafaxine(pristiq), temsirolimus(Torisel), ILS-920 and gemtuzumab ozogamicin(Mylotarg), Magid Abou-Gharbia, HMJ, 4, 317-332, 2014.
  20. “Unleashing the power of Semi-Synthesis: The Discovery of Toresil”, J.S. Skotnicki and M. Abou-Gharbia, in Orphan Drugs and Rare Diseases, Editors: David C Pryde, Michael J Palmer, RSC Publisher, 2014, 347-366.
  21. Nuclear magnetic resonance structure revealed that the human polyomavirus JC virus agnoprotein contains an α-helix encompassing the Leu/Ile/Phe-rich domain, Pascale Coric, A. Sami Saribas, Magid Abou-Gharbia, Wayne Childers, Martyn K. White, Serge Bouaziz, Mahmut Safak, J Virol, 88 (12), 6556-75, 2014.
  22. Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF-hand proteins and synergize with fluconazole in vivo, Arielle Butts, Kristy Koselny, Yeissa Chabrier-Rosello, Camille P. Semighini, Jessica C.S. Brown, Xuying Wang, Sivakumar Annadurai, Louis DiDone, Julie Tabroff,  Wayne E. Childers, Jr.,  Magid Abou-Gharbia, Melanie Wellington, Maria E. Cardenas, Hiten D. Madhani, Joseph Heitman and Damian J. Krysan,  m Bio ,Volume 5(1),e 00765-13, 2014.
  23. Discovery of Innovative Therapeutics: Today’s Realities and Tomorrow’s Vision. 2. Pharma Challenges and their Commitment to Innovation, Magid Abou-Gharbia, Wayne Childers, J Med Chem, 57, 5525-5553, 2014.
  24. Synthesis and Evaluation of Strychnos Alkaloids as MDR Reersal Agents for Cancer Cell Eradication, Gopal Sirasani, Surendrachary Munagala, Manali Phadke, Natalkia Krynetskaia, Frances Sharom, Disshartha Chaudhury, Gregory Tawa, Wayne Childers, Magid Abou-Gharbia, Evgeny Krynetskiy, and Rodrigo B. Andrade, Bioorg Med Chem, 22, 1148-1155, 2014.
  25. A Novel Assay Platform for the Detection of Translation Modulators of Spirmidine/Spermine Acetyl transferase, Oscar Perez-Leal, Magid Abou-Gharbia, John Gordon, Wayne Childers and Salim Merali, Curr Pharm Des, 20, 245-255. 2014.

 

Selected book chapters:

  1. M. Jacobs, W.E. Childers and M. Abou-Gharbia , Dopamine Partial Agonists-Discovery, Evolution and Therapeutic Potential, in “Successful Drug Discovery-Vol 4”, J. Fischer, C. Klein and W.Childers, eds., Wiley-VCH Verlag GmbH & Co., KgaA, Weinheim, Vol 4, 83-130, 2019 .
  2. Abou-Gharbia, M; Blass, B. E.; Childers, W. E., Academic Drug Discovery Centers: Key Players in the Future of the Pharmaceutical Industry, Comprehensive, Medicinal Chemistry III, Elsevier Science, ISBN9780128032008, 2017.
  3. J.S. Skotnicki and M. Abou-Gharbia,  “Unleashing the power of Semi-Synthesis: The Discovery of Toresil”, in Orphan Drugs and Rare Diseases, Editors: David C Pryde, Michael J Palmer, RSC Publisher, ISSN 978-1-84973-806-4, 347-366, 2014
  4. M. A. Abou-Gharbia and W. E. Childers, Venlafaxine and Desvenlafaxine, Selective Norepinephrine and Serotonin Reuptake Inhibitors to Treat Major Depressive Disorder, in “Analogue-Based Drug Discovery II”, J. Fischer and C. R. Ganellin, eds., Wiley-VCH Verlag GmbH & Co., KgaA, Weinheim, ISSN 978-3-5276-3003-5, pp. 507-524, 2010.
  5. M.Abou-Gharbia, Optimization of Natural Product Leads into Drug Candidates”, in “Biodiversity”, Kluwer Academic/Plenum Pub., ISSN 978-1-4613-4855-9, pp.63-70. 2002.

 

Selected presentations:

  1. “Opportunities for International Collaborations: Pharma and Academic perspectives, The Moulder Center Experiment”, invited lecture ACS Spring 2010 National Meeting, Philadelphia, PA, March 22, 2020
  2. “Discovery of Innovative Therapeutics: Pharma and Academic Perspectives”, Plenary Lecture, Pharmacy Workshop, 12th Breast-Gynecology Immunology International Cancer Conference (BGICC), Cairo, Egypt, January 9, 2020.
  3. “Precision Medicine and Cancer Drug Therapy: A Match Made in the Genes”, invited Lecture at the 12th Breast-Gynecology Immunology International Cancer Conference (BGICC), Cairo, Egypt, January 9, 2020.
  4. “Crossing Over: Drug Discovery in Pharmaceutical Industry and Academia, A personal Perspective”, Invited Lecture, Genenntech, San Francisco, CA, March 12, 2019.
  5. “Heterocycles in Drug Discovery””, Invited Lecturer, Department of Chemistry, University of Pennsylvania, Philadelphia, PA, February 6, 2019.
  6. “ Discovery and Development Strategies for Development of Innovative Therapeutics”, invited Lecture, Convalife Pharmaceuticals, Shangahai, China, January7, 2019.
  7. “Discovery of Innovative Therapeutics”, Keynote Lecture, Shanghai Haiyan Pharmaceuticals, Shanghai, China, September 3-7, 2018.
  8. “Drug Discovery Then and Now: The Road to Personalized Medicine, Keynote Lecture, Chemspec Europe, Cologne, Germany, June 20-21, 2018.
  9. “Crossing Over: A Drug Discovery Perspective from Pharma and Academia”, Keynote, 45th MALTO Meeting, Lecturer, Texas A&M University, College Station, Texas, May 25, 2018.
  10. “Drug Discovery in a changing Environment: Enhancing Innovation and benefitting Patients, Invited Lecturer at UCLA Medical Center, Los Angeles, CA, February 9, 2017.
  11. “Life After Big Pharma: Academic drug Discovery in an Ever Changing Biomedical Arena”, Invited Keynote Speaker in New Development in Medicinal Chemistry Symposium, University of Pennsylvania, Philadelphia, PA, May 6, 2017.
  12. “Approaches for the Discovery of Novel Antidepressants: The Discovery of Effexor, First in Class Serotonin Norepinephrine Reuptake Inhibitor (SNRI)”, Pfizer Effexor Launch Symposium, Tokyo, Japan, April 2, 2016
  13. “Discovery of Innovative Therapeutics: Discovery of Pristiq, Norepinephrine Reuptake Inhibitor (SNRI)”, Pfizer Neuroscience Team, Mumbai, India, April 4, 2016.
  14. Biomedical Research and Status of Drug Industry Based on Research and Innovation in Egypt and the Middle east”, Invited Speaker at Alexandria University & Military Medical Academy, Alexandria, Egypt, July 19, 2016.
  15. “Commercialization of Science: Challenges and Opportunities-The Moulder Center Experience”, American Chemical Society National Meeting, Philadelphia, PA, August 21, 2016.

 

Select Patents

  1. Novel 5-hydroxtrytamine receptor 7 activity modulators and their methods of use, Canney, Daniel J., Blass, Benjamin E., Gao, Rong, Abou-gharbia, Magid, US10,287,274, 2019.
  2. Novel 5-hydroxtrytamine receptor 7 activity modulators and their methods of use, Canney, Daniel J., Blass, Benjamin E., Gao, Rong, Abou-gharbia, Magid, US10,239,868, 2019.
  3. Anti-PCSK9 compounds and methods for the treatment and/or prevention of cardiovascular diseases, Abou-Gharbia, M.; Childers, W. E.; Martinez, R. L.; Ghidu, V.; Blass, B. E.; Abdel-Meguid, S. S.; Meyers, H. US 101,131,637, 2018.
  4. Novel 5-hydroxtrytamine receptor 7 activity modulators and their methods of use, Canney, Daniel J., Blass, Benjamin E., Gao, Rong, Abou-gharbia, Magid, US 9,802,924, 2018.
  5. Novel beta lactams as modulators of glutamate uptake and methods for use thereof, Abou-Gharbia, M.; Childers, W. E.; Martinez, R. L.; Ramanjulu, M. M.; Blass, B. E. US 9,975,879, 2018.
  6. Novel Cytochrome P450 Inhibitors and Their Method of Use, Blass, B. E., Abou-Gharbia, M., Childers, W., Iyer, P., Boruwa, J., Bobbala, R., US 9,725,436, 2017.
  7. SSAT mRNA Translation Repression and Activation, Merali, S., Perez-Leal, O., Abou-Gharbia, M., Childers, W. E., US 9,585,380, 2017.
  8. Disubstituted oxazolidin-2-ones 5-hydroxtrytamine receptor 2B activity modulators, Canney, Daniel J., Blass, Benjamin E., Gao, Rong, Abou-gharbia, Magid, US9,464,062, 2016.

Temple University
Moulder Center for Drug Discovery Research

Temple University School of Pharmacy
3307 N Broad Street
Philadelphia, PA 19140